Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients

NCT07560475 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HER2positive
Advanced Breast Cancer
HER2 + Breast Cancer

Interventions

DRUG: SHR-A1811
DRUG: SHR-A1811

Sponsor

Tianjin Medical University Cancer Institute and Hospital